PPARA and steatosis: Lanifibranor, a pan-PPAR agonist, directly activates all three PPAR isoforms (Figure 3), resulting in the PPARα-induced inhibition of steatosis in hepatocytes, PPARδ-induced reduction of hepatic macrophage infiltration, and PPARγ-induced reduction of hepatic stellate cell (HSC) activation [63].